Background and Aim: Although the Barcelona Clinic Liver Cancer (BCLC) staging system is widely used for hepatocellular carcinoma (HCC) staging, the most appropriate BCLC stage designation for single large HCC (SLHCC, single nodule >5cm) remains controversial. This study investigated the prognosis of patients with SLHCC. Methods: Patients with newly diagnosed HCCs (BCLC stages A or B) were classified according to tumor burden: group 1, a single nodule >2 and ≤5cm or two or three nodules ≤3cm; group 2, a single nodule >5cm; and group 3, two or three nodules >3cm or >3 nodules. Survival analysis was performed according to tumor stage, treatment type, and Child-Pugh grade. Results: A total of 1005 patients were enrolled. Age was 59.3±10.6years, and 788 patients (78.4%) were men. Groups 1, 2, and 3 consisted of 613 (61.0%), 124 (12.3%), and 268 (26.7%) patients, respectively. HCC treatment included resection in 202 patients (20.1%), radiofrequency ablation±transarterial chemoembolization in 311 patients (30.9%), and transarterial chemoembolization in 492 patients (49.0%). The median survival time differed significantly according to tumor stage (75.2, 44.9, and 30.3months in groups 1, 2, and 3, respectively; P<0.001). Multivariate analysis showed that group 2 had significantly worse survival compared with group 1 and similar survival to group 3. Conclusions: Patients in group 2 had a worse prognosis than those in group 1 and a similar prognosis to those in group 3. Our results suggest that BCLC stage B is the best stage designation for SLHCC.
|Number of pages||8|
|Journal||Journal of Gastroenterology and Hepatology (Australia)|
|Publication status||Published - 2016 Feb 1|
- BCLC staging system
- Single large hepatocellular carcinoma
- Treatment option
ASJC Scopus subject areas